{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Design", "EGFR", "antitumor", "inhibitor", "synthesis"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35260020", "DateCompleted": {"Year": "2022", "Month": "03", "Day": "21"}, "DateRevised": {"Year": "2022", "Month": "03", "Day": "21"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1080/14756366.2022.2046567"], "Journal": {"ISSN": "1475-6374", "JournalIssue": {"Volume": "37", "Issue": "1", "PubDate": {"Year": "2022", "Month": "Dec"}}, "Title": "Journal of enzyme inhibition and medicinal chemistry", "ISOAbbreviation": "J Enzyme Inhib Med Chem"}, "ArticleTitle": "Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors.", "Pagination": {"StartPage": "832", "EndPage": "843", "MedlinePgn": "832-843"}, "Abstract": {"AbstractText": ["This paper described our efforts to develop dianilinopyrimidines as novel EGFR inhibitors. All the target compounds were tested for inhibitory effects against wild type EGFR (EGFR<sup>wt</sup>) and three tumour cells, including A549, PC-3, and HepG2. Some of the compounds performed well in antitumor activities. Especially, compound <b>4c</b> 2-((2-((4-(3-fluorobenzamido)phenyl)amino)-5-(trifluoromethyl) pyrimidin-4-yl)amino)-<i>N</i>-methylthiophene-3-carboxamide showed higher anti-tumour activities than Gefitinib. The IC<sub>50</sub> values of compound <b>4c</b> against A549, PC-3, and HepG2. reached 0.56\u2009\u03bcM, 2.46\u2009\u03bcM, and 2.21\u2009\u03bcM, respectively. In addition, further studies indicated that compound <b>4c</b> could induce apoptosis against A549 cells and arrest A549 cells in the G2/M phase. Molecular docking studies showed that compound <b>4c</b> could closely interact with EGFR. Generally, compound <b>4c</b> was the potential for developing into an anti-tumour drug."]}, "AuthorList": [{"Identifier": ["0000-0003-3703-6704"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Guizhou University, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China."}], "LastName": "Yan", "ForeName": "Longjia", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Guizhou University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China."}], "LastName": "Wang", "ForeName": "Qin", "Initials": "Q"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Guizhou University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China."}], "LastName": "Liu", "ForeName": "Li", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Pharmaceutical Sciences, Guizhou University, Guiyang, China."}, {"Identifier": [], "Affiliation": "State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University, Guiyang, China."}, {"Identifier": [], "Affiliation": "Guizhou Engineering Laboratory for Synthetic Drugs, Guiyang, China."}], "LastName": "Le", "ForeName": "Yi", "Initials": "Y"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "J Enzyme Inhib Med Chem", "NlmUniqueID": "101150203", "ISSNLinking": "1475-6366"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Aniline Compounds"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein Kinase Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Pyrimidines"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "EGFR protein, human"}, {"RegistryNumber": "EC 2.7.10.1", "NameOfSubstance": "ErbB Receptors"}], "MeshHeadingList": [{"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Aniline Compounds"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Antineoplastic Agents"}, {"QualifierName": ["drug effects"], "DescriptorName": "Apoptosis"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Cycle"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["drug effects"], "DescriptorName": "Cell Proliferation"}, {"QualifierName": [], "DescriptorName": "Dose-Response Relationship, Drug"}, {"QualifierName": [], "DescriptorName": "Drug Design"}, {"QualifierName": [], "DescriptorName": "Drug Screening Assays, Antitumor"}, {"QualifierName": ["antagonists & inhibitors", "metabolism"], "DescriptorName": "ErbB Receptors"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Molecular Structure"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Protein Kinase Inhibitors"}, {"QualifierName": ["chemical synthesis", "chemistry", "pharmacology"], "DescriptorName": "Pyrimidines"}, {"QualifierName": [], "DescriptorName": "Structure-Activity Relationship"}], "CoiStatement": "No potential conflict of interest was reported by the author(s)."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Riihimaki M, Hemminki A, Fallah M, et al. . Metastatic sites and survival in lung cancer. Lung Cancer 2014;86:78\u201384.", "ArticleIdList": ["25130083"]}, {"Citation": "Lemjabbar-Alaoui H, Hassan OU, Yang YW, Buchanana P.. Lung cancer: biology and treatment options. Biochim Biophys Acta 2015;1856:189\u2013210.", "ArticleIdList": ["PMC4663145", "26297204"]}, {"Citation": "Al-Sanea MM, Al-Ansary GH, Elsayed ZM, et al. . Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells. J Enzyme Inhib Med Chem 2021;36:987\u201399.", "ArticleIdList": ["PMC8128204", "33985397"]}, {"Citation": "Xu K, Zhang C, Du T, et al. . Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother 2021;134:111111.", "ArticleIdList": ["33352449"]}, {"Citation": "Rotow J, Bivona TG.. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 2017;17:637\u201358.", "ArticleIdList": ["29068003"]}, {"Citation": "Fennell DA, Summers Y, Cadranel J, et al. . Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev 2016;44:42\u201350.", "ArticleIdList": ["26866673"]}, {"Citation": "Ferrer I, Zugazagoitia J, Herbertz S, et al. . KRAS-Mutant non-small cell lung cancer: from biology to therapy. Lung Cancer 2018;124:53\u201364.", "ArticleIdList": ["30268480"]}, {"Citation": "Soliman AM, Alqahtani AS, Ghorab M.. Novel sulphonamide benzoquinazolinones as dual EGFR/HER2 inhibitors, apoptosis inducers and radiosensitizers. J Enzyme Inhib Med Chem 2019;34:1030\u201340.", "ArticleIdList": ["PMC6522976", "31074303"]}, {"Citation": "Milik SN, Lasheen DS, Serya RAT, et al. . How to train your inhibitor: design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors. Eur J Med Chem 2017;142:131\u201351.", "ArticleIdList": ["28754471"]}, {"Citation": "Singh SS, Mattheolabakis G, Gu X, et al. . A grafted peptidomimetic for EGFR heterodimerization inhibition: implications in NSCLC models. Eur J Med Chem 2021;216:113312.", "ArticleIdList": ["PMC8044046", "33667849"]}, {"Citation": "Ayati A, Moghimi S, Salarinejad S, et al. . A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem 2020;99:103811.", "ArticleIdList": ["32278207"]}, {"Citation": "Gharwan H, Groninger H.. Kinase inhibitors and monoclonal antibodies in oncology: clinical implications. Nat Rev Clin Oncol 2016;13:209\u201327.", "ArticleIdList": ["26718105"]}, {"Citation": "Roskoski R. Jr., Properties of FDA-approved small molecule protein kinase inhibitors: a 2020 update. Pharmacol Res 2020;152:104609.", "ArticleIdList": ["31862477"]}, {"Citation": "Ewes WA, Elmorsy MA, El-Messery SM, et al. . Synthesis, biological evaluation and molecular modeling study of [1,2,4]-Triazolo[4,3-c]quinazolines: new class of EGFR-TK inhibitors. Bioorg Med Chem 2020;28:115373.", "ArticleIdList": ["32085964"]}, {"Citation": "Passaro A, Mok T, Peters S, et al. . Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, Non Exon 20 insertions, EGFR mutations. J Thorac Oncol 2021;16:764\u201373.", "ArticleIdList": ["33333327"]}, {"Citation": "Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncol 2018;14:1117\u201332.", "ArticleIdList": ["29336166"]}, {"Citation": "Kim ES, Melosky B, Park K, et al. . EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncol 2021;17:2395\u2013408.", "ArticleIdList": ["33855865"]}, {"Citation": "Min HY, Yun HJ, Lee JS, et al. . Targeting the insulin-like growth factor receptor and Src signaling network for the treatment of non-small cell lung cancer. Mol Cancer 2015;14:113.", "ArticleIdList": ["PMC4453276", "26041671"]}, {"Citation": "Hsu PC, Yang CT, Jablons DM, et al. . The crosstalk between Src and Hippo/YAP signaling pathways in Non-Small Cell Lung Cancer (NSCLC). Cancers 2020;12:1361.", "ArticleIdList": ["PMC7352956", "32466572"]}, {"Citation": "Filosto S, Baston DS, Chung S, et al. . Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells. Mol Cancer Ther 2013;12:1579\u201390.", "ArticleIdList": ["PMC4370317", "23686837"]}, {"Citation": "Kilic T, Alberta JA, Zdunek PR, et al. . Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000;60:5143\u201350.", "ArticleIdList": ["11016641"]}, {"Citation": "Chang S, Yin SL, Wang J, et al. . Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells. Molecules 2009;14:4166\u201379.", "ArticleIdList": ["PMC6254841", "19924055"]}, {"Citation": "Druker BJ. STI571 (Gleevec\u2122) as a paradigm for cancer therapy. Trends Mol Med 2002;8:S14\u2013S8.", "ArticleIdList": ["11927282"]}, {"Citation": "Li L, Wang Y, Jiao L, et al. . Protective autophagy decreases osimertinib cytotoxicity through regulation of stem cell-like properties in lung cancer. Cancer Lett 2019;452:191\u2013202.", "ArticleIdList": ["30910592"]}, {"Citation": "Han H, Li S, Chen T, et al. . Targeting HER2 Exon 20 insertion-mutant lung adenocarcinoma with a Novel tyrosine kinase inhibitor mobocertinib. Cancer Res 2021;81:5311\u201324.", "ArticleIdList": ["PMC8530969", "34380634"]}, {"Citation": "Pillonel C. Evaluation of phenylaminopyrimidines as antifungal protein kinase inhibitors. Pest Manag Sci 2005;61:1069\u201376.", "ArticleIdList": ["15952247"]}, {"Citation": "Cui J, Fu R, Zhou LH, et al. . BCR-ABL tyrosine kinase inhibitor pharmacophore model derived from a series of phenylaminopyrimidine-based (PAP) derivatives. Bioorg Med Chem Lett 2013;23:2442\u201350.", "ArticleIdList": ["23473682"]}, {"Citation": "Ture A, Ergul M, Ergul M, et al. . Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids. Mol Divers 2021;25:1025\u201350.", "ArticleIdList": ["32328961"]}, {"Citation": "Vlasov SV, Kovalenko SM, Shynkarenko PE, et al. . Synthesis and antimicrobial evaluation of 3-(4-arylthieno[2,3-d]pyrimidin-2-yl)- 2H-chromen-2-ones. Heterocycl Commun 2018;24:237\u201340."}, {"Citation": "Saravanan J, Mohan S, Roy JJ.. Synthesis of some 3-substituted amino-4,5-tetramethylene thieno[2,3-d][ 1,2,3]-triazin-4(3H)-ones as potential antimicrobial agents. Eur J Med Chem 2010;45:4365\u20139.", "ArticleIdList": ["20579782"]}, {"Citation": "Zhang Y, Wang Q, Li L, et al. . Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells. J Enzyme Inhib Med Chem 2021;36:1205\u201316.", "ArticleIdList": ["PMC8174486", "34074193"]}, {"Citation": "Agnew-Francis KA, Williams CM.. Squaramides as bioisosteres in contemporary drug design. Chem Rev 2020;120:11616\u201350.", "ArticleIdList": ["32930577"]}, {"Citation": "Li B, Li Y, Tomkiewicz-Raulet C, et al. . Design, synthesis, and biological evaluation of covalent inhibitors of Focal Adhesion Kinase (FAK) against human malignant glioblastoma. J Med Chem 2020;63:12707\u201324.", "ArticleIdList": ["33119295"]}, {"Citation": "Sylvester PW. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol 2011;716:157\u201368.", "ArticleIdList": ["21318905"]}, {"Citation": "Weber H, M\u00fcller D, M\u00fcller M, et al. . Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery. J Biomol Screen 2014;19:1350\u201361.", "ArticleIdList": ["25260782"]}, {"Citation": "Asquith CRM, Maffuid KA, Laitinen T, et al. . Targeting an EGFR water network with 4-Anilinoquin(az)oline inhibitors for chordoma. ChemMedChem 2019;14:1693\u2013700.", "ArticleIdList": ["31424613"]}, {"Citation": "Guo T, Ma S.. Recent advances in the discovery of multitargeted tyrosine kinase inhibitors as anticancer agents. ChemMedChem 2021;16:600\u201320.", "ArticleIdList": ["33179854"]}, {"Citation": "Asquith CRM, Naegeli KM, East MP, et al. . Design of a cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) inhibitor set to interrogate the relationship of EGFR and GAK in chordoma. J Med Chem 2019;62:4772\u20138.", "ArticleIdList": ["30973735"]}, {"Citation": "Aziz MW, Kamal AM, Mohamed KO, et al. . Design, synthesis and assessment of new series of quinazolinone derivatives as EGFR inhibitors along with their cytotoxic evaluation against MCF7 and A549 cancer cell lines. Bioorg Med Chem Lett 2021;41:127987.", "ArticleIdList": ["33771586"]}, {"Citation": "Cui Z, Chen S, Wang Y, et al. . Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment. Eur J Med Chem 2017;136:372\u201381.", "ArticleIdList": ["28525838"]}, {"Citation": "To C, Jang J, Chen T, et al. . Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discov 2019;9:926\u201343.", "ArticleIdList": ["PMC6664433", "31092401"]}, {"Citation": "Minnelli C, Laudadio E, Mobbili G, et al. . Conformational insight on WT- and mutated-EGFR receptor activation and inhibition by epigallocatechin-3-Gallate: over a rational basis for the design of selective non-small-cell lung anticancer agents. Int J Mol Sci 2020;21:1721.", "ArticleIdList": ["PMC7084708", "32138321"]}, {"Citation": "Leelananda SP, Lindert S.. Computational methods in drug discovery. Beilstein J Org Chem 2016;12:2694\u2013718.", "ArticleIdList": ["PMC5238551", "28144341"]}, {"Citation": "Darney K, Lautz LS, Bechaux C, et al. . Human variability in polymorphic CYP2D6 metabolism: implications for the risk assessment of chemicals in food and emerging designer drugs. Environ Int 2021;156:106760.", "ArticleIdList": ["34256299"]}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "3", "Day": "9", "Hour": "5", "Minute": "30"}, {"Year": "2022", "Month": "3", "Day": "10", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "22", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "3", "Day": "9"}], "PublicationStatus": "ppublish", "ArticleIdList": ["35260020", "PMC8920385", "10.1080/14756366.2022.2046567"]}}], "PubmedBookArticle": []}